PRF Technologies Ltd (PRFX) Fair Value & Analysis
Healthcare · US · Market cap $5.0M
PRF Technologies Ltd
PRFX · US
Fair value as of: Jul 19, 2026
From 1 valuation models · updated today
Share price −35.7% over the past month.
Price vs Fair Value (12 months)
12‑month range $1.18 – $11.85 · fair‑value band $0.1700 – $0.3145 · the $1.19 price screens above the $0.2550 fair value. As of Jul 19, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
PRF Technologies Ltd (PRFX) currently trades at $1.19, while our model-based Fair Value estimate is $0.2550, implying the stock looks roughly 78.6% overvalued today. We read business quality at 25/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at $17.0K. It earns a return on equity of -90.4%. The balance sheet holds a net cash position of $4.1M. Fundamentals as of Jul 19, 2026
Our scenario range runs from $0.1700 (bear case) to $0.3145 (bull case); at $1.19, the current price sits above that range. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -79%, PRFX screens richer than that median.
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jul 19, 2026. TTM = trailing twelve months.
About the company
PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company was formerly known as PainReform Ltd. and changed its name to PRF Technologies Ltd. in January 2026. PRF Technologies Ltd. was incorporated in 2007 and is based in Tel Aviv-Yafo, Israel.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PRF Technologies Ltd reported revenue of $17.0K in FY2025 versus $0 in FY2021. Reported net income was −$4.8M in FY2025.
Is PRFX fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.01 | ¥26.59 | -43% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| PharmaEssentia Corporation 6446 | 1,160 TWD | 258.12 TWD | -78% |
| Cipla Limited CIPLA | ₹1,416 | ₹1,466 | +4% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Lupin Limited LUPIN | ₹2,340 | ₹2,477 | +6% |
| Mankind Pharma Limited MANKIND | ₹2,538 | ₹1,161 | -54% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PRF Technologies Ltd (PRFX) undervalued?
What is the fair value of PRFX?
What is the quality score of PRFX?
What is the revenue of PRF Technologies Ltd (PRFX)?
What is the net profit margin of PRFX?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full PRF Technologies Ltd analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.